Extension Study MT-1186-A04 Evaluating Oral Edaravone (Radicava ORS®) Continued Efficacy and Safety up to an Additional 48 Weeks in Patients With ALS (P9-2.007)

Continue to examine the efficacy and safety of investigational once daily and FDA-approved on/off Radicava ORS® (edaravone) oral suspension (Mitsubishi Tanabe Pharma America [MTPA], hereafter “MTPA oral edaravone”) dosing regimens in patients with amyotrophic lateral sclerosis (ALS) for up to an additional 48 weeks in extension Study MT-1186-A04.